Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

Ads

You May Also Like

Delårsrapport 1 januari – 30 september 2018

     Väsentliga händelser under perioden 1 januari till 30 september AroCell ingick ett icke ...

ContraFect Announces Second Quarter 2018 Financial Results

YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...

Radius Health Appoints Jessica Hopfield, Ph.D., to Board of Directors

WALTHAM, Mass., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the ...